GenX intergenerational mentoring program for Virus Infection, RNA

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
UCLA School of Medicine, Los Angeles, CA
Virus Infection, RNA+1 More
GenX intergenerational mentoring program - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This randomized controlled trial will test whether a recently developed community-based intergenerational mentoring program known as Generation Xchange (GenX) can enhance antiviral resistance in older African-American women and men in a low-SES urban community. Additional studies will identify the biological processes that promote resistance to respiratory virus infections and viral disease in older African-American women and men.

Eligible Conditions

  • Virus Infection, RNA

Treatment Effectiveness

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 10 months

10 months
Antiviral cell prevalence
Antiviral gene regulation
Concentration of Type I interferon antiviral activity (bioassay International Units / mL)
Depressive symptoms
Loneliness
Pro-inflammatory cytokine concentration (pg/mL)
Respiratory virus antibody concentration (WHO international units BAU/mL)
Well-being

Trial Safety

Trial Design

2 Treatment Groups

Delayed GenX
1 of 2
Immediate GenX
1 of 2
Active Control
Experimental Treatment

160 Total Participants · 2 Treatment Groups

Primary Treatment: GenX intergenerational mentoring program · No Placebo Group · N/A

Immediate GenX
Behavioral
Experimental Group · 1 Intervention: GenX intergenerational mentoring program · Intervention Types: Behavioral
Delayed GenX
Behavioral
ActiveComparator Group · 1 Intervention: GenX intergenerational mentoring program · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 10 months
Closest Location: UCLA School of Medicine · Los Angeles, CA
Photo of Los Angeles 1Photo of Los Angeles 2Photo of Los Angeles 3
2010First Recorded Clinical Trial
1 TrialsResearching Virus Infection, RNA
44 CompletedClinical Trials

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,381 Previous Clinical Trials
6,520,987 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,348 Previous Clinical Trials
3,261,737 Total Patients Enrolled
Steven Cole, Ph.D.Principal InvestigatorProfessor of Medicine & Psychiatry
Teresa E Seeman, Ph.D.Principal InvestigatorProfessor of Medicine

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You live in a neighborhood that is within a one-mile radius of a GenX school.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.